125 related articles for article (PubMed ID: 10188884)
1. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.
O'Byrne KJ; Dobbs N; Propper DJ; Braybrooke JP; Koukourakis MI; Mitchell K; Woodhull J; Talbot DC; Schally AV; Harris AL
Br J Cancer; 1999 Mar; 79(9-10):1413-8. PubMed ID: 10188884
[TBL] [Abstract][Full Text] [Related]
2. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM
Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187
[TBL] [Abstract][Full Text] [Related]
3. A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer.
Wolff AC; Armstrong DK; Fetting JH; Carducci MK; Riley CD; Bender JF; Casero RA; Davidson NE
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5922-8. PubMed ID: 14676116
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer.
Joensuu TK; Nilsson S; Holmberg AR; Márquez M; Tenhunen M; Saarto T; Joensuu H
Ann N Y Acad Sci; 2004 Dec; 1028():361-74. PubMed ID: 15650261
[TBL] [Abstract][Full Text] [Related]
5. No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery.
Sancak B; Coskun U; Gunel N; Onuk E; Cihan A; Karamercan A; Yildirim Y; Ozkan S
Intern Med J; 2004 Jun; 34(6):310-5. PubMed ID: 15228391
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of somatostatin analogue RC-160 on the growth of hepatic metastases of colon cancer in rats: a study with magnetic resonance imaging.
Qin Y; Van Cauteren M; Osteaux M; Schally AV; Willems G
Cancer Res; 1992 Nov; 52(21):6025-30. PubMed ID: 1356623
[TBL] [Abstract][Full Text] [Related]
8. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
9. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
10. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
11. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
13. Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study.
Gebbia V; Borsellino N; Testa A; Tirrito M; Varvara F; Cucchiara A; Mauceri G; Girlando A; Ferrara M; Caruso F
Anticancer Res; 1999; 19(4C):3553-7. PubMed ID: 10629652
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
15. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
Pieńkowski T; Jagiello-Gruszfeld A
Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
18. [Plasma-prolactin concentrations in breast cancer at various stages, in mastopathy and other malignant tumors].
Holtkamp W; von Heyden D; Rauschecker H; Nagel GA
Schweiz Med Wochenschr; 1983 Oct; 113(41):1513-20. PubMed ID: 6635641
[TBL] [Abstract][Full Text] [Related]
19. Serum methionine depletion without side effects by methioninase in metastatic breast cancer patients.
Tan Y; Zavala J; Xu M; Zavala J; Hoffman RM
Anticancer Res; 1996; 16(6C):3937-42. PubMed ID: 9042316
[TBL] [Abstract][Full Text] [Related]
20. [Prolactin and human cancer of the breast. I. Levels of correlation].
Cueto Ladrón de Guevara J; Villalba Moreno J; García Puche JL; Pedraza V
Rev Esp Oncol; 1985; 32(3):439-58. PubMed ID: 3870536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
